Free newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.
Prices, providers, and published evidence — tracked independently, never an affiliate code. Get research updates as the data grows.
Free · occasional research updates only · unsubscribe in one click
Already a member? Sign in
Peptide Profile
Advanced Obesity Drug 9604 · hGH Fragment 176-191 · Fragment 176-191 · HGH Frag 176-191 · Frag 176-191 · AOD 9604 · AOD9604
AOD-9604 (anti-obesity drug 9604; Tyr-hGH(177–191)) is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic fragment of human growth hormone, modified with an N-terminal tyrosine residue for stability, and…
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.
AOD-9604 (anti-obesity drug 9604; Tyr-hGH(177–191)) is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic fragment of human growth hormone, modified with an N-terminal tyrosine residue for stability, and investigated as a candidate anti-obesity compound on the premise that the lipolytic activity of hGH resides in this C-terminal domain — separable from the growth-promoting and insulin-antagonizing effects mediated by other regions of the full-length molecule. AOD-9604 is proposed to stimulate fat metabolism through beta-3 adrenergic receptor-mediated pathways without activating IGF-1 production or the anabolic receptor domains of full-length GH, making it theoretically safer than GH itself for metabolic applications; a 2001 preclinical study in obese mice (PMID 11713213) demonstrated lipolytic effects and body weight reduction via this mechanism. Clinical trials were conducted in humans by Metabolic Pharmaceuticals, and Phase 2/3 data generated in Australia suggested modest weight loss effects; however, the primary trial results were never published in PubMed-indexed peer-reviewed journals, and the best indexed primary evidence for AOD-9604 remains that preclinical mouse study. AOD-9604 has no FDA approval and no approved indication in any jurisdiction; despite its human clinical program, the absence of published peer-reviewed primary trial data means clinical efficacy and safety cannot be independently evaluated, and no validated human dosing protocol has been established. The compound is currently available only as a research peptide. AOD-9604 is supplied as a lyophilized powder for research use; oral formulations were also evaluated in the clinical program as an alternative to subcutaneous delivery, though no commercial oral AOD-9604 product reached market. AOD-9604 evidence limitations The primary indexed evidence base for AOD-9604 consists of a 2001 preclinical study in obese mice (PMID 11713213) demonstrating beta-3 adrenergic receptor-mediated lipolysis and body weight reduction without IGF-1 elevation or blood glucose disruption. The Phase 2/3 human clinical program conducted by Metabolic Pharmaceuticals generated obesity trial data, but those primary results were never published in PubMed-indexed peer-reviewed journals, meaning the human efficacy and safety dataset cannot be independently evaluated. No validated human dosing protocol has been established for AOD-9604 in any jurisdiction, and no approved clinical indication exists. The absence of published human trial data represents a fundamental gap that precludes definitive statements about clinical efficacy, optimal administration, or long-term safety. AOD-9604 side effects and safety profile The safety data from AOD-9604's clinical program includes several notable findings: no elevation in IGF-1 levels was observed at studied doses — a key distinction from full-length growth hormone, where IGF-1 elevation drives concerns about cell proliferation and potential oncogenicity. No significant disruption of fasting glucose or insulin sensitivity was documented. No serious adverse events attributable to AOD-9604 were reported in published trial summaries. The absence of anabolic receptor activity (no binding to the GH receptor growth-promoting domain) is the proposed basis for this benign safety profile compared to GH itself. Long-term safety data does not exist due to the absence of Phase 3 completion and product approval. Research-grade AOD-9604 carries standard purity and contamination risks associated with unregulated compounding. Providers offering AOD-9604 through supervised clinical programs are searchable in the PeptideBase provider directory.
Commonly researched in the context of
Population research notes
These signals reflect research interest areas, not treatment indications.
Compound & timing
Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.
based on 1 study · dated evidence base — most recent 2001
HGH fragment 176-191. Drug development terminated 2007 (Phase 3 failure). FDA GRAS notice GRN 000792 for food ingredient use only — not a drug approval. No active NDA. Research chemical.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
1 source cited · 1 moderate
1 Animal
The effect of the growth hormone fragment AOD9604 on adipose tissue
Endocrinology · 2001
Research in obese mouse models demonstrated that AOD9604, a C-terminal fragment of human growth hormone, stimulated lipolysis and reduced fat mass via beta-3 adrenergic receptor activation without affecting insulin-like growth factor-1 levels or blood glucose, suggesting a targeted fat-reducing mechanism.
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Median tested purity
99.6%
Median tested purity of 99.6% across 4 verified third-party lab COAs (interquartile range 99.4%–99.8%), as reported by the independent testing lab below. PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
AOD-9604 - 5mg · Lot AD05-06 · Jul 8, 2026 · View source COA
99.7%
Purity
AOD9604 10mg · Lot V3312329682 · Jul 2, 2026 · View source COA
99.8%
Purity
AOD-9604 · Jun 17, 2026 · View source COA
99.2%
Purity
AOD-9604 · Lot AOD002 · Jun 16, 2026
AOD-9604 · May 26, 2026 · View source COA
99.5%
Purity
AOD-9604 · Lot AD-01-LD · May 25, 2026
AOD-9604 · Lot BP-3713888 · May 23, 2026 · View source COA
99.7%
Purity
AOD-9604 · Lot BP-3713888-E · May 23, 2026
AOD-9604 · Lot HGF001 · May 5, 2026
AOD-9604 · Apr 23, 2026 · View source COA
99.7%
Purity
AOD-9604 · Mar 9, 2026 · View source COA
99.8%
Purity
AOD-9604 · Mar 9, 2026 · View source COA
99.8%
Purity
HGH-Frag 176-191 · Lot FP25-1006 · Sep 29, 2025
99.8%
Purity
AOD-9604 5mg · Lot AOD09222025-J · Sep 25, 2025 · View source COA
99.7%
Purity
AOD-9604 5mg · Lot AOD09082025-J · Sep 13, 2025 · View source COA
99.7%
Purity
AOD-9604 · Lot 254282 · Sep 10, 2025
99.7%
Purity
AOD 9604 · Lot AD26 · Sep 10, 2025 · View source COA
99.6%
Purity
AOD-9604 5mg · Lot AOD08252025-J · Aug 28, 2025 · View source COA
99.5%
Purity
AOD-9604 · Lot FP25-0025 · Apr 23, 2025
99.2%
Purity
PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Verified results come from an independent third-party lab database lookup. Vendor-published results are reported by the vendor itself and have not been independently verified by PeptideBase or a third-party lab.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Self-reported, anecdotal experiences aggregated from public Reddit discussions — community sentiment, not clinical evidence or medical advice.
Attribution note: many of these reports describe stacking AOD-9604 with other compounds, so outcomes may not be attributable to it alone.
Outcome distribution
Outcomes by goal · improved % · reports
Most reported
What they wish they'd known
Based on 7 community reports · Updated
AOD-9604 (anti-obesity drug 9604; Tyr-hGH(177–191)) is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic fragment of human growth hormone, modified with an N-terminal tyrosine residue for stability, and investigated as a candidate anti-obesity compound on the premise that the lipolytic activity of hGH resides in this C-terminal domain — separable from the growth-promoting and insulin-antagonizing effects mediated by other regions of the full-length molecule. AOD-9604 is proposed to stimulate fat metabolism through beta-3 adrenergic receptor-mediated pathways without activating IGF-1 production or the anabolic receptor domains of full-length GH, making it theoretically safer than GH itself for metabolic applications; a 2001 preclinical study in obese mice (PMID 11713213) demonstrated lipolytic effects and body weight reduction via this mechanism.
selective fat tissue lipolysis via GH C-terminal fragment mechanism, adipose metabolism stimulation without IGF-1 elevation, originally developed to isolate GH lipolytic effect from growth effects, subcutaneous injection — reconstitution with bacteriostatic water required.
Research on AOD-9604 primarily documents effects related to selective fat tissue lipolysis via GH C-terminal fragment mechanism and adipose metabolism stimulation without IGF-1 elevation and originally developed to isolate GH lipolytic effect from growth effects and subcutaneous injection — reconstitution with bacteriostatic water required. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
For AOD-9604, its FDA status is Nomination Withdrawn, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
148 providers in the directory currently offer AOD-9604.
Across 61 research vendors tracked on PeptideBase, AOD-9604 has a median price of about $9.00 per mg, typically ranging $7.46–$12.15 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.
Research in obese mouse models demonstrated that AOD9604, a C-terminal fragment of human growth hormone, stimulated lipolysis and reduced fat mass via beta-3 adrenergic receptor activation without affecting insulin-like growth factor-1 levels or blood glucose, suggesting a targeted fat-reducing mechanism.
AOD-9604 is featured in the following research stacks on PeptideBase: AOD-9604 + Tirzepatide: Advanced Body Composition.
Price per mg varies by quantity, vendor type, and formulation. Research use only.
Data verified July 2026 · AOD-9604 price intelligence
AMAVA Regenerative Medicine Peoria-Glendale AZ
Apex Health & Wellness
Carvalho Healthcare
Center for Advanced Urology
Evolve Wellness Clinic
Florida Regenerative
Hawaii Natural Medicine
Hormone & Peptide Therapy Greenville SC
Hydrology Wellness
Commonly stacked with
Stay updated on verified AOD-9604 providers
New verified providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). AOD-9604 — Per-mg Price Benchmark. Retrieved July 22, 2026, from https://peptidebase.io/peptides/aod-9604